AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.

about

AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.

Item

http://www.wikidata.org/entity/Q48240243

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

AHNS Series: Do you know your ...... neck squamous cell carcinoma.

@en

AHNS Series: Do you know your ...... neck squamous cell carcinoma.

@nl

type

Item

label

AHNS Series: Do you know your ...... neck squamous cell carcinoma.

@en

AHNS Series: Do you know your ...... neck squamous cell carcinoma.

@nl

prefLabel

AHNS Series: Do you know your ...... neck squamous cell carcinoma.

@en

AHNS Series: Do you know your ...... neck squamous cell carcinoma.

@nl

P1476

AHNS Series: Do you know your ...... d neck squamous cell carcinoma

@en

P2093

Education Committee of the American Head and Neck Society (AHNS)

http://www.w3.org/2001/XMLSchema#string

Thomas J Ow

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy.

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

P304

676-686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HED.25025

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Missak Haigentz

Cory D Fulcher

P577

2017-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29171929

http://www.w3.org/2001/XMLSchema#string

P932

5849482

http://www.w3.org/2001/XMLSchema#string